Aptevo Therapeutics Inc. (APVO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+379114.3%

$5,119.39

vs $1.35 price

Levered DCF

$5,385.10

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-33.17

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.11×	-0.05×	-0.13×	1.47×	-1.3×	-3.87×	-0.04×	-0.53×
P/B	0×	0.25×	0.18×	0.66×	30.34×	7.49×	0×	0×
P/S	0×	0×	0×	3.8×	3×	28.84×	0×	0×
EV / EBITDA	0.66×	0.08×	0.42×	0.97×	-1.29×	-7.85×	-0.26×	0.23×
Gross margin	0.0%	0.0%	0.0%	100.0%	100.0%	-314.3%	0.0%	51.4%
Operating margin	0.0%	0.0%	0.0%	-919.7%	-174.1%	-638.1%	0.0%	-224.0%
Net margin	0.0%	0.0%	0.0%	257.8%	-231.5%	-411.9%	0.0%	-232.8%
Current ratio	3.82×	1.72×	2.64×	3.15×	1.51×	3.25×	0.78×	2.76×
Debt / equity	0.27×	0.97×	0.44×	0.53×	13.75×	1.65×	1.96×	0.63×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-149.4%	-507.5%	-142.5%	44.7%	-2340.2%	-107.0%	-377.5%	-176.6%
Return on invested capital	-119.5%	-262.2%	-163.9%	-104.1%	-63.9%	-62.5%	-116.9%	-103.6%
Return on assets	-95.5%	-154.8%	-70.1%	23.5%	-50.3%	-33.1%	-83.7%	-79.5%
Free cash flow yield	-86018.8%	-1998.6%	-526.6%	-177.9%	-60.7%	-23.7%	0.0%	0.0%
Earnings yield	-87279.2%	-2027.6%	-781.6%	67.8%	-77.1%	-14.3%	0.0%	0.0%
Enterprise value	-$16.9M	-$2M	-$7.6M	$7.7M	$36.4M	$205.5M	$10.7M	-$11.4M
Net debt / EBITDA	0.66×	0.17×	0.64×	-1.66×	1×	0.48×	-0.26×	0.23×
Cash conversion cycle (days)	-1,334	-3,166	0	293	109	201	-1,127	-239